Sarcopenia Market 2024-2034

1
Sarcopenia Market Research Report 2024-2034
2
ABOUT IMARC
International Market Analysis Research and
Consulting Group is a leading adviser on
management strategy and market research
worldwide. We partner with clients in all regions
and industry verticals to identify their
highest-value opportunities, address their most
critical challenges, and transform their
businesses. IMARCs information products include
major market, scientific, economic and
technological developments for business leaders
in pharmaceutical, industrial, and high
technology organizations. Market forecasts and
industry analysis for biotechnology, advanced
materials, chemicals, food and beverage, travel
and tourism, nanotechnology and novel processing
methods are at the top of the companys
expertise. IMARCs tailored approach combines
unfathomable insight into the dynamics of
companies and markets with close cooperation at
all levels of the client organization. This
ensures that our clients achieve unmatchable
competitive advantage, build more proficient
organizations, and secure lasting results.
3
Report Description and Highlights

• Sarcopenia Market Report Overview
• Report Attribute Details
• Base Year
  2023
• Forecast Years 2024-2034
• Historical Years 2018-2023
• Market Size in 2023 US 1.5
  Billion
• Market Forecast in 2034 US 2.3
  Billion
• Market Growth (2024-2034) 4.1
• The report offers a comprehensive analysis of the
  Sarcopenia market in the United States, EU5
  (including Germany, Spain, Italy, France, and the
  United Kingdom), and Japan. It covers aspects
  such as treatment methods, drugs available in the
  market, drugs in development, the proportion of
  various therapies, and the market's performance
  in the seven major regions. Additionally, the
  report evaluates the performance of leading
  companies and their pharmaceutical products.
  Current and projected patient numbers across
  these key markets are also detailed in the
  report.

4
Report Description and Highlights

• This study is essential for manufacturers,
  investors, business planners, researchers,
  consultants, and anyone interested or involved in
  the Sarcopenia market.
• Market Overview
• The 7 major sarcopenia markets reached a value of
  US 1.5 Billion in 2023. Looking forward, IMARC
  Group expects the 7MM to reach US 2.3 Billion by
  2034, exhibiting a growth rate (CAGR) of 4.1
  during 2024-2034.

5
Report Description and Highlights

• The sarcopenia market is gaining increasing
  attention and investment due to a convergence of
  factors. Sarcopenia, characterized by muscle loss
  and decreased strength, often accompanied by
  reduced functionality in older adults, is at the
  center of this growing interest. One of the
  primary drivers fueling the expansion of the
  sarcopenia market is the rise in the aging
  population. As the proportion of geriatric
  individuals continues to grow, age-related
  conditions like sarcopenia become more prevalent,
  leading to a higher demand for interventions and
  treatments. Awareness campaigns and extensive
  scientific research on muscle decline associated
  with aging are driving interest and funding in
  the sarcopenia market. This has resulted in the
  development of specialized exercise programs,
  pharmaceuticals, and nutritional supplements
  designed to alleviate symptoms. Innovations in
  diagnostic methods, including DXA scans and MRI,
  have enhanced the detection and monitoring of
  sarcopenia, enabling timely intervention, which
  is crucial for effective treatment. In certain
  regions, healthcare policies have been revised to
  encompass treatments for age-related conditions,
  offering financial incentives to individuals
  seeking treatment.
• This policy shift further augments the market
  potential for sarcopenia products and services.
  The recent emphasis on preventive healthcare and
  wellness has created a conducive environment for
  addressing the onset and progression of
  sarcopenia.

6
Report Description and Highlights

• Protein supplements and exercise equipment
  tailored to build muscle mass in older adults are
  gaining popularity. Additionally, the increased
  utilization of resistance and strength training
  to treat the condition by enhancing muscle
  protein synthesis and supporting muscular
  strength is another significant growth-inducing
  factor. Collaborations between academic
  institutions, healthcare providers, and biotech
  companies are expediting research and product
  development, which is expected to contribute
  significantly to the growth of the sarcopenia
  market in the coming years.
• Request a Sample Report https//www.imarcgroup.co
  m/sarcopenia-market/requestsample

7
Report Description and Highlights

• What is included in the report segmentation?
• The report covers the following aspects
• Report Period
• Base Year 2023
• Historical Period 2018-2023
• Market Forecast 2024-2032
• Countries Included
• United States
• Germany
• France

8
Report Description and Highlights

• United Kingdom
• Italy
• Spain
• Japan
• Analysis Covered Across Each Country
• Historical, current, and future epidemiology
  scenario
• Historical, current, and future performance of
  the Sarcopenia market
• Historical, current, and future performance of
  various therapeutic categories in the market
• Sales of various drugs across the Sarcopenia
  market
• Reimbursement scenario in the market
• In-market and pipeline drugs
• This report also provides a detailed analysis of
  the current Sarcopenia marketed drugs and
  late-stage pipeline drugs.

9
Report Description and Highlights

• In-Market Drugs
• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
• Late-Stage Pipeline Drugs
• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
• View Report TOC, Figures and Tables
  https//www.imarcgroup.com/sarcopenia-market

10
Report Description and Highlights

• Competitive Landscape With Key Players
• The competitive landscape of the Sarcopenia
  market has been studied in the report with the
  detailed profiles of the key players operating in
  the market.
• Ask Analyst for Customization and Explore Full
  Report With TOC List of Figures
  https//www.imarcgroup.com/request?typereportid
  7323flagC
• If you need specific information that is not
  currently within the scope of the report, we will
  provide it to you as a part of the customization.
• About Us
• IMARC Group is a leading market research company
  that offers management strategy and market
  research worldwide. We partner with clients in
  all sectors and regions to identify their
  highest-value opportunities, address their most
  critical challenges, and transform their
  businesses.
• IMARCs information products include major
  market, scientific, economic and technological
  developments for business leaders in
  pharmaceutical, industrial, and high technology
  organizations. Market forecasts and industry
  analysis for biotechnology, advanced materials,
  pharmaceuticals, food and beverage, travel and
  tourism, nanotechnology and novel processing
  methods are at the top of the companys expertise.

11
Report Description and Highlights

• Media Contact
• Company Name IMARC Group
• Contact Person Elena Anderson
• Email sales_at_imarcgroup.com
• Phone [phone]
• Address 134 N 4th St
• City Brooklyn
• State NY
• Country United States
• Website https//www.imarcgroup.com/

12
Key Questions Answered in the Report

1. How has the Sarcopenia market performed so far
   and how will it perform in the coming years?
2. What are the markets shares of various
   therapeutic segments in 2023 and how are they
   expected to perform till 2034?
3. What was the country-wise size of the Sarcopenia
   market across the seven major markets in 2023 and
   what will it look like in 2034?
4. What is the growth rate of the Sarcopenia market
   across the seven major markets and what will be
   the expected growth over the next ten years?
5. What are the key unmet needs in the market?

13
Table of Contents
14
Table of Contents

• 1 Preface
• 2 Scope and Methodology
• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
• 2.3.1 Primary Sources
• 2.3.2 Secondary Sources
• 2.4 Market Estimation
• 2.4.1 Bottom-Up Approach
• 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology
• 3 Executive Summary

15
Table of Contents

• 4 Sarcopenia - Introduction
• 4.1 Overview
• 4.2 Regulatory Process
• 4.3 Epidemiology (2018-2023) and Forecast
  (2024-2034)
• 4.4 Market Overview (2018-2023) and Forecast
  (2024-2034)
• 4.5 Competitive Intelligence
• 5 Sarcopenia - Disease Overview
• 5.1 Introduction
• 5.2 Symptoms and Diagnosis
• 5.3 Pathophysiology
• 5.4 Causes and Risk Factors
• 5.5 Treatment
•    Click here to visit the complete table of
  content with list of figures and tables
  https//www.imarcgroup.com/sarcopenia-market/toc

16
Partial List Of Our Clients
17
OUR CLIENTS
18
Disclaimer
2024 IMARC All Rights Reserved This
Publication and all its contents unless
otherwise mentioned are copyrighted in the name
of International Market Analysis Research and
Consulting (IMARC). No part of this publication
may be reproduced, repackaged, redistributed or
resold in whole or in any part. The publication
may also not be used in any form or by and means
graphic electronic or mechanical, including
photocopying, recording, taping or by information
storage or retrieval, or by any other form,
without the express consent of International
Market Analysis Research and Consulting
(IMARC). Disclaimer All contents and data of
this publication, including forecasts, data
analysis and opinion have been based on
information and sources believed to be accurate
and reliable at the time of publishing.
International Market Analysis Research and
Consulting makes no representation of warranty of
any kind as to the accuracy or completeness of
any Information provided. IMARC accepts no
liability whatsoever for any loss or damage
resulting from opinion, errors or inaccuracies if
any found this publication. IMARC, IMARC Group
and Global Therapy Insight Series are registered
trademarks of International Market Analysis
Research and Consulting. All other trademarks
used in this publication are registered
trademarks of their respective companies.